Effect of 32P Application Combined with Timolol Maleate on Circulating Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Children with Cutaneous Hemangioma
Effect of 32P Application Combined with Timolol Maleate on Circulating Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Children with Cutaneous Hemangioma
Zongliang Li1, Rongxin Ma2,*, Yan Wei1 and Jianghua Zuo3
ABSTRACT
The aim of this study was to investigate the effect of 32P application combined with timolol maleate on circulating vascular endothelial growth factor and basic fibroblast growth factor in children with cutaneous hemangioma. Eighty children with hemangioma treated in the Provincial Women and Children’s Hospital from May 2018 to April 2019 were enrolled in the study, including 37 males and 43 females. The children were randomized into two groups according to the experiment: the conventional treatment group (taking one tablet of propranolol) and the combination treatment group (topical application of timolol maleate and 32P application). mRNA expression of VEGF and TGF-b was increased in the conventional treatment group compared with the combination treatment group (P<0.05). The protein expression of bFGF and IL-6 in the combined treatment group was lower than that in the conventional treatment group (P<0.05). The conventional treatment group 30 (75.00%) had a lower tumor growth rate (P<0.05) than the combination treatment group (92.50%), and the combined treatment group 32 (80.00%) had a significantly reduced tumor depth compared with the conventional treatment group 21 (52.50%). There was no difference in the rate of bronchospasm between the conventional treatment group and the combination treatment group (P>0.05). 32P application combined with timolol maleate has a good therapeutic effect on hemangiomas, which can reduce the expression of circulating vascular endothelial growth factor and basic fibroblast growth factor.
To share on other social networks, click on any share button. What are these?
June 2023
Vol. 55, Iss. 3, Pages 1003-1500
